🔴 Recursion Pharmaceuticals is trading at 4.7% down today alongside biotech ETF XBI's 2.50% decline

Recursion Pharmaceuticals is trading 4.7% lower at $4.55, with biotech-sector weakness a possible backdrop.

• Biotech ETF XBI is down 2.50%; no clear company-specific announcement explaining the October 6 decline surfaced in available coverage.
• The recent Tempus agreement, extending the data partnership and licensing Recursion’s RNA model, was linked to the prior session’s rally and does not clearly explain the reversal.
• Major indexes are higher, so the broader market direction does not align with the decline.